Bulletin du cancer · 1997
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Клиническое исследованиеКлиническое исследование II фазыАннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baranzelli M C, Pichon F, Gourmel B, N'Guyen M, Deligny N, Demaille M C
Аннотация
Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma. To try to find a possible dose-effect, 10 patients with advanced pretraited relapsed soft tissue sarcoma received 15 g/m2/cycle ifosfamide in continuous infusion during 5 days. A pharmacokinetic study was done for 2 patients. All patients received growth factors, ondansetron and 8 clonazepam. Renal toxicity was evaluated after the first and the second cycle. Twenty two cycles were delivered to patients who have been already treated with ifosfamid (10 patients with 15 g/m2 to 54 g/m2, median 27 g/m2) or cis platinum (2 patients). No major renal or neurologic toxicity was observed; only subclinical modifications of urinary enzymes excretion were found. Two patients had visual hallucinations at the end of a cycle and just in the 2 following days; another presented a neuropathy of inferior limbs. Hematological toxicity was very limited. Pharmacokinetic study did not show induction mechanism at this dosage and with this type of administration. So ifosfamide 3 g/m2 during 5 days is feasible. The few level of complications observed is perhaps linked to the daily dose of 3 g/m2 instead of 4 g/m2 or more used in the other studies.
Предметные рубрики MeSH
AdultAgedAnticonvulsantsAntineoplastic Agents, AlkylatingClonazepamDose-Response Relationship, DrugDrug Administration ScheduleFeasibility StudiesFemaleGranulocyte Colony-Stimulating FactorHumansIfosfamideInfusions, IntravenousKidney DiseasesMaleMiddle AgedNervous System DiseasesSarcomaSoft Tissue Neoplasms